RxDoctor Payments Data

Betsy Rentschler, NP

Family · Sioux Falls, SDNPI 1598010662

Payments from drug & device makers

$1,175in general payments, 2019–2025

Across 47 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$612
  • AbbVie$271
  • Coloplast$94
  • Hologic Sales And Service, LLC$62
  • Astellas Pharma US Inc$46
  • Bluewind Medical$29
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$1,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic19$612
AbbVie(2 entities)15$271
Coloplast5$94
Hologic Sales And Service, LLC1$62
Astellas Pharma US Inc3$46
Bluewind Medical1$29
Axonics, Inc.1$26
Rochester Medical Corporation1$20
Neurocrine Biosciences, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175 in reported general payments places this provider in the 75th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$22,728
Medicare patients
237
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron301$140,039
GemtesaVibegron43$15,938
Estradiol183$10,050
EstringEstradiol11$5,603
Mirabegron ErMirabegron13$3,814
Trospium Chloride91$3,255
Cephalexin314$2,403
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst64$1,835
Oxybutynin Chloride ErOxybutynin Chloride35$982
Clobetasol Propionate23$932
Gabapentin33$642
Fluconazole49$438
Silver Sulfadiazine30$349
LoperamideLoperamide Hcl16$335
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen80$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$46$140,039301 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →